Top Markets
Coin of the day
GlycoNex Incorporation GlycoNex Incorporation

GlycoNex Incorporation

4168
Rank in Stocks #22943
GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in... GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target validation stage. Beyond oncology, GlycoNex is also advancing other therapeutic agents. This includes SPD (Denosumab), a humanized IgG2 antibody in preclinical stages for both osteoporosis and oncology indications. Another key asset is SEA (Aflibercept), a vascular endothelial growth factor (VEGF) binding fusion protein, currently undergoing lead optimization for its potential use in ophthalmology and oncology. GlycoNex was established in 2001.
Share Price
$0.71865803
Last synced: 2026-08-21
Market Cap
$80.86M
Change (1 day)
0.00%
Change (1 year)
-5.48%
Country
TW
Trade GlycoNex Incorporation (4168)

Category

Stock price history for GlycoNex Incorporation (4168)
Highest end of day price: $0.72 on 2026-08-01

Lowest end of day price: $2.55 on 2012-06-01
Stock price history of GlycoNex Incorporation from 2012 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) 4.61%
2025 -1.85%
2024 -14.27%
2023 -16.58%
2022 0.65%
2021 19.55%
2020 36.23%
2019 -14.54%
2018 0.91%
2017 -26.75%
2016 -41.27%
2015 -21.61%
2014 -32.30%
2013 -27.14%
2012 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH